Oragenics, Inc. (NYSEMKT:OGEN) Files An 8-K Entry into a Material Definitive Agreement
Item1.01
| Entry into a Material Definitive Agreement. |
Loan Commitment Letter
On April18, 2017, Oragenics, Inc. (the Company) entered into a
commitment letter (the Commitment Letter) with Intrexon
Corporation (Intrexon) one of our largest shareholders and our
partner on certain of our development programs. The Commitment
Letter provides for Intrexon to make an unsecured non-convertible
loan (the Loan) to the Company in the principal amount of
$2.4million. The Loan would be repayable within 24 months and
carry an interest rate of 12% per annum. The funds from the Loan
would be used to fund our AG013 research and clinical trials.The
Loan under the Commitment Letter is conditioned upon the Company
obtaining other financing of least $2.7million and other
customary closing conditions.
The foregoing description of the Commitment Letter is filed as
Exhibit 10.1 to this Current Report on Form 8-K and is
incorporated by reference herein.
| Item7.01 | Regulation FD Disclosure. |
On April18, 2017, the Company intends to post an investor
presentation prepared by the Company (the Investor Presentation)
which it also expects to use from time to time in connection with
presentations to potential investors, industry analysts and
others. The Investor Presentation, which is available under the
Presentations tab in the News and Media section of the Companys
website, located at www.oragenics.com, is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
By filing this Current Report on Form 8-K and furnishing the
information contained herein, the Company makes no admission as
to the materiality of any information in this report that is
required to be disclosed solely by reason of Regulation FD.
The information contained in the Investor Presentation is summary
information that is intended to be considered in the context of
the Companys Securities and Exchange Commission (SEC) filings and
other public announcements that the Company may make, by press
release or otherwise, from time to time. The Company undertakes
no duty or obligation to publicly update or revise the
information contained in this report, although it may do so from
time to time as its management believes is warranted. Any such
updating may be made through the filing of other reports or
documents with the SEC, through press releases or through other
public disclosure.
The information presented in Item 7.01 of this Current Report on
Form 8-K and Exhibit 99.1 shall not be deemed to be filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, unless the Company specifically
states that the information is to be considered filed under the
Exchange Act or specifically incorporates it by reference into a
filing under the Securities Act of 1933, as amended, or the
Exchange Act.
| Item8.01 | Other Events. |
On April18, 2017, the Company issued a press release providing an
update regarding the progress of its two lead product candidates,
AG013 for the treatment of oral mucositis and OG716 for the
treatment of Clostridium difficile (C. diff). A
copy of this press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 10.1 | Loan Commitment Letter dated April18, 2017. | |
| 99.1 | Investor Presentation | |
| 99.2 | Press Release dated April18, 2017 |
About Oragenics, Inc. (NYSEMKT:OGEN)
Oragenics, Inc. develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering. MU1140 is an antibiotic that is produced by the parent of the SMaRT strain. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145. LPT3-04 is a compound, which is consumed in the human diet in small amounts and results in dose-dependent weight loss in experimental animal models. Oragenics, Inc. (NYSEMKT:OGEN) Recent Trading Information
Oragenics, Inc. (NYSEMKT:OGEN) closed its last trading session 00.000 at 0.380 with 38,557 shares trading hands.
